Methylsulfonylmethane inhibits NLRP3 inflammasome activation

Cytokine

Volumn 71, Issue 2, 2015, Pages 223-231

  Ahn, Huijeong ^a   Kim, Jeeyoung ^a   Lee, Min Jae ^a   Kim, Young Jin ^b   Cho, Young Wook ^c   Lee, Geun Shik ^a  

^a Kangwon National University   (South Korea)

^b Korea Food Research Institute   (South Korea)

^c Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

DMSO; Inflammasome; Interleukin 1beta; Macrophages; MSM

Indexed keywords

CRYOPYRIN; DIMETHYL SULFONE; DIMETHYL SULFOXIDE; INFLAMMASOME; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN AIM2; PROTEIN NLCR4; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; CARRIER PROTEIN; CYTOKINE; NLRP3 PROTEIN, HUMAN; SULFONE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE CONTROL; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MACROPHAGE; METABOLIC DISORDER; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPPLEMENTATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOBLOTTING; IMMUNOLOGY; LISTERIA MONOCYTOGENES; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; CELLS, CULTURED; CYTOKINES; DIMETHYL SULFOXIDE; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOBLOTTING; INFLAMMASOMES; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LISTERIA MONOCYTOGENES; MACROPHAGES; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALMONELLA TYPHIMURIUM; SULFONES;

EID: 84911416633     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.001     Document Type: Article

References (38)

1. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327:296-300.
2. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011, 11:213-220.
3. Lee G.S. Inflammasomes, multi-cellular protein complex in myeloid cells, induce several metabolic diseases via interleukin-1β maturation. J Biomed Res 2013, 14:195-200.
4. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O'Neill L., et al. IL-1 family nomenclature. Nat Immunol 2010, 11:973.
5. Henao-Mejia J., Elinav E., Thaiss C.A., Flavell R.A. Inflammasomes and metabolic disease. Annu Rev Physiol 2014, 76:57-78.
6. Pearson T.W., Dawson H.J., Lackey H.B. Natural occurring levels of dimethyl sulfoxide in selected fruits, vegetables, grains, and beverages. J Agric Food Chem 1981, 29:1089-1091.
7. Richmond V.L. Incorporation of methylsulfonylmethane sulfur into guinea pig serum proteins. Life Sci 1986, 39:263-268.
8. Kim L.S., Axelrod L.J., Howard P., Buratovich N., Waters R.F. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society. 2006, 14:286-294.
9. Jacob S.W., Herschler R. Pharmacology of DMSO. Cryobiology 1986, 23:14-27.
10. Ahn H., Kim J., Jeung E.B., Lee G.S. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology 2014, 219:315-322.
11. Kim J., Ahn H., Han B.C., Lee S.H., Cho Y.W., Kim C.H., et al. Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation. Immunol Lett 2014, 158:143-150.
12. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
13. Sauer J.D., Witte C.E., Zemansky J., Hanson B., Lauer P., Portnoy D.A. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe 2010, 7:412-419.
14. Warren S.E., Armstrong A., Hamilton M.K., Mao D.P., Leaf I.A., Miao E.A., et al. Cutting edge: cytosolic bacterial DNA activates the inflammasome via Aim2. J Immunol 2010, 185:818-821.
15. Zhao Y., Yang J., Shi J., Gong Y.N., Lu Q., Xu H., et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011, 477:596-600.
16. Kim Y.H., Kim D.H., Lim H., Baek D.Y., Shin H.K., Kim J.K. The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biol Pharm Bull 2009, 32:651-656.
17. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009, 183:787-791.
18. Bianchini F., Vainio H. Allium vegetables and organosulfur compounds: do they help prevent cancer?. Environ Health Perspect 2001, 109:893-902.
19. Brien S., Prescott P., Bashir N., Lewith H., Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis and cartilage/OARS, Osteoarthritis Research Society. 2008, 16:1277-1288.
20. Morton J.I., Siegel B.V. Effects of oral dimethyl sulfoxide and dimethyl sulfone on murine autoimmune lymphoproliferative disease. Proc Soc Exp Biol Med 1986, 183:227-230.
21. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 2010, 10:210-215.
22. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
23. Li Y., Trush M.A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun 1998, 253:295-299.
24. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:333-342.
25. Amirshahrokhi K., Bohlooli S., Chinifroush M.M. The effect of methylsulfonylmethane on the experimental colitis in the rat. Toxicol Appl Pharmacol 2011, 253:197-202.
26. Kamel R., El Morsy E.M. Hepatoprotective effect of methylsulfonylmethane against carbon tetrachloride-induced acute liver injury in rats. Arch Pharmacal Res 2013, 36:1140-1148.
27. Ezaki J., Hashimoto M., Hosokawa Y., Ishimi Y. Assessment of safety and efficacy of methylsulfonylmethane on bone and knee joints in osteoarthritis animal model. J Bone Miner Metab 2013, 31:16-25.
28. Nakhostin-Roohi B., Barmaki S., Khoshkhahesh F., Bohlooli S. Effect of chronic supplementation with methylsulfonylmethane on oxidative stress following acute exercise in untrained healthy men. J Pharm Pharmacol 2011, 63:1290-1294.
29. Jin C., Frayssinet P., Pelker R., Cwirka D., Hu B., Vignery A., et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci USA 2011, 108:14867-14872.
30. Pujol J.P., Chadjichristos C., Legendre F., Bauge C., Beauchef G., Andriamanalijaona R., et al. Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res 2008, 49:293-297.
31. Kloesch B., Liszt M., Broell J., Steiner G. Dimethyl sulphoxide and dimethyl sulphone are potent inhibitors of IL-6 and IL-8 expression in the human chondrocyte cell line C-28/I2. Life Sci 2011, 89:473-478.
32. Santos N.C., Figueira-Coelho J., Martins-Silva J., Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003, 65:1035-1041.
33. Phillis J.W., Estevez A.Y., O'Regan M.H. Protective effects of the free radical scavengers, dimethyl sulfoxide and ethanol, in cerebral ischemia in gerbils. Neurosci Lett 1998, 244:109-111.
34. Robbins G.R., Wen H., Ting J.P. Inflammasomes and metabolic disorders: old genes in modern diseases. Mol Cell 2014, 54:297-308.
35. Masters S.L., Dunne A., Subramanian S.L., Hull R.L., Tannahill G.M., Sharp F.A., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010, 11:897-904.
36. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
37. Stienstra R., Tack C.J., Kanneganti T.D., Joosten L.A., Netea M.G. The inflammasome puts obesity in the danger zone. Cell Metab 2012, 15:10-18.
38. Hoffman H.M., Scott P., Mueller J.L., Misaghi A., Stevens S., Yancopoulos G.D., et al. Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice. Arthritis Rheum 2010, 62:2170-2179.